: #587c19; font-family: ; line-height: 30px"> Safety and effectiveness are supported by certain data
The effectiveness of AstraZeneca vaccine is reduced by 3%, India now has double mutant virus | New Crown Weekly Research Progress
Time of Update: 2021-04-13
effectiveness by 3%>AstraZeneca updated the vaccine data, the effectiveness decreased by 3% AstraZeneca updated the vaccine
Diabetes Care: The new hypoglycemic drug imiglitazone effectively improves HbA1c in patients with type 2 diabetes
Time of Update: 2021-04-13
Compared with placebo, imiglitazone can significantly improve the HbA1c of Japanese T2DM patients, and its safety is similar to that of placebo.
Diabetes Care: New hypoglycemic drugs can effectively improve Asian cardiovascular risk
Time of Update: 2021-04-13
Compared with whites, Asians may gain greater cardiovascular death/ heart failure benefits from SGLT2is, and in patients with type 2 diabetes, MACE benefits from GLP-1RAs.
AstraZeneca announces safety and effectiveness of phase 3 clinical trial of new crown vaccine
Time of Update: 2021-04-13
On March 25, local time, AstraZeneca's official website announced that the preliminary analysis results of the phase III clinical trial of the new crown vaccine AZD1222 were consistent with the interim analysis results announced on March 22.
Cell: The new crown vaccine has a long way to go: a variety of COVID-19 variants evade neutralization through vaccine-induced humoral immunity
Time of Update: 2021-03-30
The mutations of the spike protein sequence of the following SARS-CoV-2 variant strains are as follows: wild type (Gray ) , D614G ( pink ) , B.
JAMA: The effect of increasing the dose of preventive anticoagulant therapy on the prognosis of ICU patients with new coronary pneumonia
Time of Update: 2021-03-30
7%) in the enoxaparin medium-dose group had the primary endpoint event, while the standard-dose prevention group was 126 cases (44.
and will be used to evaluate the effectiveness of the new crown vaccine
Time of Update: 2021-03-30
This cooperation will promote GenScript's cPass SARS-CoV-2 neutralizing antibody detection kit to be widely used in 24 regions throughout the Middle East and North Africa to evaluate the effectiveness of the new coronary pneumonia vaccine.
AstraZeneca announces Phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness
Time of Update: 2021-03-29
>
On March 25, AstraZeneca announced that the main analysis of the Phase 3
The protective effect reaches 79%, without increasing the risk of thrombosis, AstraZeneca announces
Time of Update: 2021-03-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
Nature: Leprosy drugs can effectively fight the new coronavirus infection
Time of Update: 2021-03-27
Studies have found that clofamizine, the drug currently used to treat leprosy, is effective against SARS-CoV-2 infection in human cells and hamster models.
3 NEJM articles on the same day: Post-vaccination infection is a case, and the new crown vaccine is generally effective for medical staff
Time of Update: 2021-03-27
on the safety of vaccinations for over 60,000 people, reducing 92% of new crown infections and 94% of cases. NEJM published data on Pfizer/BioNTech vaccines for 600,000 people in Israel. Source: 123RF reference materials [1] Jocelyn
JAMA: The effect of increasing the dose of preventive anticoagulant therapy on the prognosis of ICU patients with new coronary pneumonia
Time of Update: 2021-03-26
7%) in the enoxaparin medium-dose group had the primary endpoint event, while the standard-dose prevention group was 126 cases (44.
Cell: The new crown vaccine has a long way to go: a variety of COVID-19 variants evade neutralization through vaccine-induced humoral immunity
Time of Update: 2021-03-26
The mutations of the spike protein sequence of the following SARS-CoV-2 variant strains are as follows: wild type (Gray ) , D614G ( pink ) , B.
and will be used to evaluate the effectiveness of the new crown vaccine
Time of Update: 2021-03-26
This cooperation will promote GenScript's cPass SARS-CoV-2 neutralizing antibody detection kit to be widely used in 24 regions throughout the Middle East and North Africa to evaluate the effectiveness of the new coronary pneumonia vaccine.
In vitro test: mutant new coronavirus discovered in South Africa may reduce the effect of Pfizer vaccine
Time of Update: 2021-03-25
;">Hot Article Selections of 2020 1. The cup is ready! A full paper cup of hot coffee, full of plastic particles. . . 2.
